ABSTRACT
Precision medicine is changing the way cancer is tested and treated in the US, but a lack of standardization and barriers to collaboration between oncologists, payers and genomic testing labs has been slowing its use.
In fact, the gap between how oncologists and payers make oncology care decisions has never been greater, and it is impeding the application of life-saving therapies.
The solution? The battle royale between payers and oncologists must end to ensure cancer patients are getting the most appropriate precision testing and therapies at the right stage of their treatment journeys. But how?
INSIDE THE WHITEPAPER:
-
What is causing the “battle royale” between oncologists and payers
-
Why we need a modern prior authorization process
-
How to close the gap and bring precision medicine to more patients
Cancer is among the top five most expensive diseases that account for over 80% of all health care spending and those costs are expected to increase to $246 billion by 2030.
CONTRIBUTORS:
Debra Patt, M.D., Ph.D., MBA
Health economics and health services research oncologist and breast cancer expert at Texas Oncology
Russ Ingersoll, Ph.D.
Chief Product Officer and pharmacology and toxicology expert at Trapelo Health
Learn More
Sign up and receive more insights on the latest advances, opinions, and news in precision medicine decision support.
